Sandoz to commercialize Taiwan Liposome's antifungal

19 December 2013

Taipei-based biopharmaceutical company Taiwan Liposome Company (TLC; 4152: TWO) has entered into a collaboration agreement with Sandoz, the generics division of Swiss drug major Novartis (NOVN: VX).

Sandoz will be responsible for the commercialization of TLC's liposomal amphotericin B, an antifungal and an antiprotozoal medicine, in European Union and US territories. TLC’s Abelcet branded amphotericin B lipid complex product received its first market approval in the UK in 1995.

"We are very pleased to have an extremely strong player in the generic market such as Sandoz to distribute our Liposomal Amphotericin B product in EU and US," said Keelung Hong, chairman and chief executive of TLC, adding: "We also anticipate this deal to be a collaborative relationship between TLC and Sandoz, which I'm sure both parties would benefit tremendously from."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK